AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25428176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5% (4 drops daily)
Number of subjects: 18
Study 25428176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide hydrochloride 2% (3 drops daily)
Number of subjects: 18
Study 24407835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography and ultrasonography (standardized examination)
Number of subjects: 76196
Study 24407835 — intervention group
Group type: COMPARATOR
Intervention: Mammography (control group)
Number of subjects: 76196
Study 22837629 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% with lidocaine 2%
Number of subjects: 150
Study 22837629 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% with lidocaine 2%
Number of subjects: 150
Study 19884468 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 57
Study 19884468 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 57
Study 17578316 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI) in cooperation with chemotherapy (CAF protocol)
Number of subjects: 110
Study 17578316 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CAF protocol) alone
Number of subjects: 110
Study 15163260 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus mood stabilizer (mean dose 3.8 mg/day during the 3-week study and 3.1 mg/day during the 10-week study)
Number of subjects: 156
Study 15163260 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus mood stabilizer
Number of subjects: 156
Study 15163260 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus mood stabilizer
Number of subjects: 156
Study 11298104 — intervention group
Group type: EXPERIMENTAL
Intervention: 1072 nm narrow waveband light application (single 5 min treatment)
Number of subjects: 0
Study 11298104 — intervention group
Group type: COMPARATOR
Intervention: Topical aciclovir (applied five times daily)
Number of subjects: 0
Study 9869347 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with bioresorbable barrier membranes
Number of subjects: 23
Study 9869347 — intervention group
Group type: COMPARATOR
Intervention: Access flap surgery
Number of subjects: 23
Study 9869347 — intervention group
Group type: COMPARATOR
Intervention: Access flap surgery in shallow defects (INFRA ≤3 mm)
Number of subjects: 23
Study 9869347 — intervention group
Group type: COMPARATOR
Intervention: Access flap surgery in deep defects (INFRA ≥4 mm)
Number of subjects: 23
Study 9869347 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) in shallow defects
Number of subjects: 23
Study 9869347 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) in deep defects
Number of subjects: 23
Study 9869347 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 23
Study 8018978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg/day
Number of subjects: 61
Study 8018978 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg/day
Number of subjects: 61
Study 2685599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod-liver oil
Number of subjects: 18
Study 2685599 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 18
Study 10874 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate feedback during treatment
Number of subjects: 10
Study 10874 — intervention group
Group type: COMPARATOR
Intervention: Instructions to lower heart rate without feedback
Number of subjects: 10
Study 10874 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate feedback added to instructions
Number of subjects: 10
Study 10874 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control of heart rate with biofeedback
Number of subjects: 10
Study 10874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment training in self-control of heart rate with feedback
Number of subjects: 10
Study 31818818 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day artemether-lumefantrine regimen
Number of subjects: 96
Study 31818818 — intervention group
Group type: COMPARATOR
Intervention: 3-day artemether-lumefantrine regimen
Number of subjects: 96
Study 30476489 — intervention group
Group type: EXPERIMENTAL
Intervention: WheelSeeU (peer-led program)
Number of subjects: 40
Study 30476489 — intervention group
Group type: COMPARATOR
Intervention: Control group (professional-led didactic information sessions)
Number of subjects: 40
Study 26917627 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (in addition to standard medical care)
Number of subjects: 182
Study 25967378 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-mind-spirit intervention (n = 56)
Number of subjects: 120
Study 25967378 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (n = 64)
Number of subjects: 120
Study 23935161 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia intervention group (n = 18)
Number of subjects: 35
Study 23935161 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 35
Study 21114478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily for 24 weeks (group A)
Number of subjects: 60
Study 21114478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin at 0·25‐0·4 mg kg⁻¹ daily for 24 weeks (group B)
Number of subjects: 60
Study 21114478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily for 1 week out of every 4 weeks for 6 weeks (group C)
Number of subjects: 60
Study 21114478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin at 0·25‐0·4 mg kg⁻¹ daily (group B)
Number of subjects: 60
Study 21114478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily (group A)
Number of subjects: 60
Study 21114478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily for 1 week out of every 4 weeks (group C)
Number of subjects: 60
Study 21114478 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (group A)
Number of subjects: 60
Study 21114478 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose treatment (group B)
Number of subjects: 60
Study 21114478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment (group C)
Number of subjects: 60
Study 21114478 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 1 year (group A)
Number of subjects: 60
Study 21114478 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 1 year (group B)
Number of subjects: 60
Study 21114478 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 1 year (group C)
Number of subjects: 60
Study 19360238 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid sinus massage (CSM) performed in the supine position for 10 seconds
Number of subjects: 502
Study 17084325 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety-inducing, bursting balloon
Number of subjects: 81
Study 17084325 — intervention group
Group type: COMPARATOR
Intervention: Nonbursting balloon
Number of subjects: 81
Study 15627789 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD) in FMF-amyloidosis patients
Number of subjects: 40
Study 15627789 — intervention group
Group type: COMPARATOR
Intervention: Diabetes mellitus (DM) patients
Number of subjects: 40
Study 15627789 — intervention group
Group type: COMPARATOR
Intervention: FMF-amyloidosis patients
Number of subjects: 40
Study 11242425 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (n = 16) modeled on the Baby‐Friendly Hospital Initiative emphasizing health care worker assistance with initiating and maintaining breastfeeding and lactation and postnatal breastfeeding support.
Number of subjects: 17046
Study 11242425 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (n = 16)
Number of subjects: 17046
Study 11242425 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (n = 15) of continuing usual infant feeding practices and policies.
Number of subjects: 17046
Study 9577500 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated catheter (n = 47)
Number of subjects: 91
Study 9577500 — intervention group
Group type: COMPARATOR
Intervention: Identical catheter without silver coating (n = 44)
Number of subjects: 91
Study 9577500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (n = 72 completion venograms)
Number of subjects: 91
Study 8004602 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for breast cancer
Number of subjects: 5
Study 8004602 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern mammography
Number of subjects: 5
Study 3504404 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 40
Study 3504404 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 40
Study 28140705 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifunctional airbag abdominal pressure belt during the second and third stages of labor
Number of subjects: 363
Study 28140705 — intervention group
Group type: COMPARATOR
Intervention: Control group (no belt used)
Number of subjects: 363
Study 28140705 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifunctional airbag abdominal pressure belt
Number of subjects: 363
Study 27126851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visits (NHV)
Number of subjects: 600
Study 27126851 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mental health (MH)
Number of subjects: 600
Study 27126851 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mastery
Number of subjects: 600
Study 27126851 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking
Number of subjects: 600
Study 27126851 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms (FKBP5 rs1360780, 5‐HTTLPR, DRD2/ANKK1 rs1800497)
Number of subjects: 600
Study 25057981 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigative CT protocol with iterative reconstruction at conventional radiography dose levels
Number of subjects: 38
Study 25057981 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigative CT protocol
Number of subjects: 38
Study 22429944 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 93
Study 22429944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 20039196 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week Internet-based cognitive-behavioral treatment
Number of subjects: 124
Study 20039196 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 124
Study 18541100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of meglumine antimoniate (20 mg Sb/kg/day, maximum 850 mg) for 21 days
Number of subjects: 60
Study 18541100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of meglumine antimoniate (0.5 mL, 42.5 mg of Sb) into each lesion along with intramuscular injection of meglumine antimoniate (20 mg Sb/kg/day, maximum 850 mg) for 21 days
Number of subjects: 60
Study 18541100 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 16326295 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium group (2.5 g magnesium sulphate infusion intraoperatively over 30 minutes)
Number of subjects: 160
Study 16326295 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (normal saline solution)
Number of subjects: 160
Study 12819504 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal approach (TEP) repair
Number of subjects: 134
Study 12819504 — intervention group
Group type: COMPARATOR
Intervention: Open mesh repair
Number of subjects: 134
Study 11119180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-dose training combined with cash reinforcement (CD+CR)
Number of subjects: 55
Study 11119180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue-dose training (CD)
Number of subjects: 55
Study 11119180 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 55
Study 11119180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash-reinforced group (CD+CR)
Number of subjects: 55
Study 9049196 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol administration
Number of subjects: 14
Study 9049196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8327595 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (0.035 IU/kg body weight)
Number of subjects: 30
Study 8327595 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned stimulus (CS)
Number of subjects: 30
Study 8327595 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 30
Study 3755281 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP (mitomycin C, doxorubicin, and cisplatin)
Number of subjects: 130
Study 3755281 — intervention group
Group type: COMPARATOR
Intervention: CAP (cyclophosphamide, doxorubicin, and cisplatin)
Number of subjects: 130
Study 29534874 — intervention group
Group type: EXPERIMENTAL
Intervention: VT‐1161 150 mg once daily for 7 days, then 150 mg once weekly for 11 weeks, followed by a once‐weekly dose of placebo for 12 weeks
Number of subjects: 215
Study 29534874 — intervention group
Group type: EXPERIMENTAL
Intervention: VT‐1161 300 mg once daily for 7 days, then 300 mg once weekly for 11 weeks, followed by a once‐weekly dose of placebo for 12 weeks
Number of subjects: 215
Study 29534874 — intervention group
Group type: EXPERIMENTAL
Intervention: VT‐1161 150 mg once daily for 7 days, then 150 mg once weekly for 23 weeks
Number of subjects: 215
Study 29534874 — intervention group
Group type: EXPERIMENTAL
Intervention: VT‐1161 300 mg once daily for 7 days, then 300 mg once weekly for 23 weeks
Number of subjects: 215
Study 29534874 — intervention group
Group type: COMPARATOR
Intervention: Placebo regimen for 24 weeks
Number of subjects: 215
Study 27234671 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly teriparatide therapy for 72 weeks
Number of subjects: 0
Study 24719911 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2605541
Number of subjects: 425
Study 24719911 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 425
Study 23291317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice administered during and after exercise for over a 2-month period
Number of subjects: 15
Study 23291317 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate supplementation (control group)
Number of subjects: 15
Study 21159597 — intervention group
Group type: EXPERIMENTAL
Intervention: RSA performed within 1 hour after skin closure
Number of subjects: 24
Study 21159597 — intervention group
Group type: EXPERIMENTAL
Intervention: RSA performed at 1 day after surgery
Number of subjects: 24
Study 21159597 — intervention group
Group type: EXPERIMENTAL
Intervention: RSA performed at 7 days after surgery
Number of subjects: 24
Study 18303533 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical nephrectomy
Number of subjects: 0
Study 18303533 — intervention group
Group type: COMPARATOR
Intervention: Open radical nephrectomy
Number of subjects: 0
Study 16911143 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision aid
Number of subjects: 1152
Study 16911143 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet decision aid
Number of subjects: 1152
Study 16911143 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1152
Study 14714355 — intervention group
Group type: EXPERIMENTAL
Intervention: Milkvetch Injection (15 ml every 12 hrs for 7 days)
Number of subjects: 32
Study 14714355 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 32
Study 10946527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.3 mg)
Number of subjects: 402
Study 10946527 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (20 mg)
Number of subjects: 402
Study 9063919 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms sufentanil in 50 ml 0.125% bupivacaine (group 1)
Number of subjects: 45
Study 9063919 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms clonidine in 50 ml 0.125% bupivacaine (group 2)
Number of subjects: 45
Study 9063919 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms sufentanil + 150 micrograms clonidine in 50 ml 0.125% bupivacaine (group 3)
Number of subjects: 45
Study 31652452 — intervention group
Group type: EXPERIMENTAL
Intervention: PHOX2B rs28647582 T>C polymorphism (TC/CC genotypes)
Number of subjects: 145
Study 31652452 — intervention group
Group type: COMPARATOR
Intervention: TT genotype
Number of subjects: 145
Study 29119331 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% DAA diet
Number of subjects: 480
Study 29119331 — intervention group
Group type: EXPERIMENTAL
Intervention: 107% DAA diet
Number of subjects: 480
Study 29119331 — intervention group
Group type: EXPERIMENTAL
Intervention: 114% DAA diet
Number of subjects: 480
Study 29119331 — intervention group
Group type: EXPERIMENTAL
Intervention: All DAA levels
Number of subjects: 480
Study 26896318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (MgSO4)
Number of subjects: 190
Study 26896318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 24974817 — intervention group
Group type: EXPERIMENTAL
Intervention: AREDS supplements (placebo, antioxidants (vitamin C, vitamin E, β-carotene), zinc, or a combination)
Number of subjects: 1237
Study 24974817 — intervention group
Group type: EXPERIMENTAL
Intervention: AREDS supplements
Number of subjects: 1237
Study 22323011 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical pleurectomy
Number of subjects: 160
Study 22323011 — intervention group
Group type: COMPARATOR
Intervention: Pleural abrasion with minocycline
Number of subjects: 160
Study 18317179 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive exercise countermeasure with whole-body vibration
Number of subjects: 20
Study 18317179 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 20
Study 17187005 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane 35 (cyproterone acetate 2 mg with ethinylestradiol 35 µg) for 6 months
Number of subjects: 25
Study 17187005 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 healthy women, mean age 26.0±2.6 years)
Number of subjects: 25
Study 17187005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin levels
Number of subjects: 25
Study 14733989 — intervention group
Group type: EXPERIMENTAL
Intervention: New safety training curriculum
Number of subjects: 0
Study 14733989 — intervention group
Group type: COMPARATOR
Intervention: Usual training
Number of subjects: 0
Study 10852597 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous double kidney transplantation (SDKT) from donors aged 75 years or older.
Number of subjects: 181
Study 10852597 — intervention group
Group type: COMPARATOR
Intervention: Single kidney transplantation from donors aged 60-74 years with GE <15%.
Number of subjects: 181
Study 10852597 — intervention group
Group type: COMPARATOR
Intervention: Single kidney transplantation from donors <60 years of age.
Number of subjects: 181
Study 10852597 — intervention group
Group type: COMPARATOR
Intervention: All groups (I, II, III) for primary nonfunction rate.
Number of subjects: 181
Study 10852597 — intervention group
Group type: COMPARATOR
Intervention: All groups (I, II, III) for acute rejection rates.
Number of subjects: 181
Study 10852597 — intervention group
Group type: COMPARATOR
Intervention: All groups (I, II, III) for one year actuarial patient survival rates.
Number of subjects: 181
Study 10852597 — intervention group
Group type: COMPARATOR
Intervention: All groups (I, II, III) for graft survival rates.
Number of subjects: 181
Study 10852597 — intervention group
Group type: COMPARATOR
Intervention: All groups (I, II, III) for 6-month serum creatinine levels.
Number of subjects: 181
Study 9086582 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 (0.6 microgram/kg bolus)
Number of subjects: 0
Study 9086582 — intervention group
Group type: COMPARATOR
Intervention: T3 (0.2 microgram/kg bolus, 0.4 microgram/kg infusion over 6 hours)
Number of subjects: 0
Study 8412266 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin and vindesine chemotherapy
Number of subjects: 209
Study 8412266 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 209
Study 2870661 — intervention group
Group type: EXPERIMENTAL
Intervention: Akrinor
Number of subjects: 0
Study 2870661 — intervention group
Group type: EXPERIMENTAL
Intervention: etilefrine
Number of subjects: 0
Study 2870661 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine
Number of subjects: 0
Study 2870661 — intervention group
Group type: EXPERIMENTAL
Intervention: norfenefrine
Number of subjects: 0
Study 2870661 — intervention group
Group type: EXPERIMENTAL
Intervention: ameziniummetilsulfate
Number of subjects: 0
Study 2870661 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30586843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cashew nuts (42 g/day)
Number of subjects: 18
Study 30586843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cashew-containing diet
Number of subjects: 18
Study 30586843 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 18
Study 27097695 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 47
Study 24306767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer (Yamax LS2000)
Number of subjects: 122
Study 24306767 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer (ActiGraph GT1M/GT3X+)
Number of subjects: 122
Study 24306767 — intervention group
Group type: EXPERIMENTAL
Intervention: Both instruments (Pedometer and Accelerometer)
Number of subjects: 122
Study 23301476 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular therapy based on the pattern/syndrome differentiation
Number of subjects: 200
Study 23301476 — intervention group
Group type: COMPARATOR
Intervention: Conventional auricular point sticking therapy
Number of subjects: 200
Study 20938590 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk introduced before four months of life
Number of subjects: 354
Study 20938590 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding for shorter than six months
Number of subjects: 354